Devon Medical extriCARE wound therapy device wins FDA nod

9 April 2012 (Last Updated April 9th, 2012 18:30)

The US Food & Drug Administration (FDA) has granted 510(k) clearance to market Devon Medical Products' extriCARE 2400 negative pressure wound therapy (NPWT) system.

FDA

The US Food & Drug Administration (FDA) has granted 510(k) clearance to market Devon Medical Products' extriCARE 2400 negative pressure wound therapy (NPWT) system.

The extriCARE 2400 pump device combines with anatomically fitted bandages which provide negative pressure (suction) to create tight seals around various areas of the body.

Together, these technologies draw blood to the wound bed and remove exudates into a disposable canister to help increase wound healing time and decrease time spent on wound care preparation, the company said.

Devon Medical Products president John Bennett said the company designed and built the extriCARE NPWT system with patients and caregivers in mind, after discussions with expert wound care nurses, physicians and wound management thought leaders.

"Ease of application, portability and bandages creating airtight seals were deemed the most vital features necessary for safe and effective wound closure," Bennett added.

"The extriCARE encompasses these traits, and we're excited to offer this innovation in negative pressure wound therapy to healthcare professionals and patients."

The extriCARE 2400 pump is intended for the management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, diabetic and pressure ulcers, flaps and grafts.

The device helps in reducing wound preparation time and can be utilised in acute hospital settings, wound clinics, nursing homes and inside the home, under supervision of a trained healthcare professional.

Image: Devon Medical's extriCARE 2400 wound therapy system has been granted FDA approval. Photo: FDA.